In This Article:
Can-Fite BioPharma has secured a US patent for Namodenoson, its lead drug candidate, for use as an anti-obesity treatment.
Set to be issued in February 2025, the patent will expire in 2042 and covers the oral administration of the drug to reduce fat levels and body weight.
The US Patent Office has accepted patent application No 17/309,952, titled "An A3 adenosine receptor ligand for use for achieving a fat loss effect," which is supported by the data showing Namodenoson's ability to decrease fat cell levels by increasing adiponectin, a hormone that regulates fat production.
The drug was shown to decrease body weight in an experimental animal model of obesity.
Can-Fite CE and CFO Motti Farbstein stated: “Namodenoson is currently being developed for the treatment of MASH in a Phase IIb study where most patients are obese. We look forward to seeing the anti-obesity effect in this clinical study.”
Currently under development for several conditions including metabolic dysfunction-associated steatohepatitis (MASH), pancreatic cancer and advanced liver cancer, the drug showed a favourable safety profile when taken orally, as determined in clinical studies.
In a Phase IIa study for MASH, subjects treated with the drug experienced a 2.3% weight loss over three months, accompanied by a significant increase in serum adiponectin levels.
The drug's selectivity to the A3 adenosine receptor, which is highly expressed in diseased cells, contributes to its safety profile.
Can-Fite has a portfolio of approved patents worldwide for clinical applications of Namodenoson.
The drug has also received orphan drug status in the US and Europe.
It also gained fast-track designation from the US Food and Drug Administration as a second-line treatment for hepatocellular carcinoma.
"Can-Fite BioPharma secures US patent for Namodenoson" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.